Klaus Pfizenmaier
Stuttgart, BW 70569, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Comparison of antibody-scTRAIL Fc fusion proteins with varying valency for EGFR and TRAIL receptors.
Comparison of antibody-scTRAIL Fc fusion proteins with varying valency for EGFR and TRAIL receptors.
Journal: Scientific reports
Published: December 02, 2024
Single intracerebroventricular TNFR2 agonist injection impacts remyelination in the cuprizone model.
Single intracerebroventricular TNFR2 agonist injection impacts remyelination in the cuprizone model.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: October 28, 2024
Tumor necrosis factor receptor 2 activation elicits sex-specific effects on cortical myelin proteins and functional recovery in a model of multiple sclerosis.
Journal: Brain research bulletin
Published: September 30, 2023
Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis.
Journal: Journal of neuroinflammation
Published: February 01, 2023
Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS.
Journal: Journal of neuroinflammation
Published: February 01, 2023
The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration.
Journal: Scientific reports
Published: October 11, 2022
Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF.
Journal: Nature immunology
Published: October 20, 2021
The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation.
Journal: Frontiers in immunology
Published: May 05, 2021
Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F-induced disease.
Journal: Blood advances
Published: February 04, 2021
A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells.
Journal: Frontiers in pharmacology
Published: March 13, 2020
Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.
Journal: Frontiers in cell and developmental biology
Published: February 06, 2020
TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice.
TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice.
Journal: Cell death & disease
Published: November 19, 2019
Last Updated: 09/26/2026